Literature DB >> 6412267

D-amphetamine in obsessive-compulsive disorder.

T R Insel, J A Hamilton, L B Guttmacher, D L Murphy.   

Abstract

In a double-blind crossover study, single doses of d-amphetamine and placebo were administered to 12 patients with severe chronic obsessive-compulsive disorder (OCD). Improvement of obsessional symptoms was significant on clinical ratings and was correlated with improved performance on an attention task. Changes were also significant for self-rated measures of activation and altered reality. The behavior response to amphetamine was not statistically correlated with subsequent improvement during a 6-week clomipramine trial, although the direction of change was the same during both treatments for every patient studied.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6412267     DOI: 10.1007/BF00436159

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

1.  Treatment of obsessive compulsive neurosis: pharmacological approach.

Authors:  J Ananth
Journal:  Psychosomatics       Date:  1976       Impact factor: 2.386

2.  Attenuation of the euphoriant and activating effects of d- and l-amphetamine by lithium carbonate treatment.

Authors:  D P Van Kammen; D L Murphy
Journal:  Psychopharmacologia       Date:  1975-11-21

3.  Amphetamine effects in man: paradoxical drowsiness and lowered electrical brain acitivity (CNV).

Authors:  J J Tecce; J O Cole
Journal:  Science       Date:  1974-08-02       Impact factor: 47.728

4.  Stereotyped activities produced by amphetamine in several animal species and man.

Authors:  A Randrup; I Munkvad
Journal:  Psychopharmacologia       Date:  1967

5.  Treatment of obsessive-compulsive neurosis.

Authors:  M Z Hussain; A Ahad
Journal:  Can Med Assoc J       Date:  1970-09-26       Impact factor: 8.262

6.  Perseverative behaviour after amphetamine; dissociation of response tendency from reward association.

Authors:  R M Ridley; H F Baker; T A Haystead
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia.

Authors:  D P van Kammen; W E Bunney; J P Docherty; S R Marder; M H Ebert; J E Rosenblatt; J N Rayner
Journal:  Am J Psychiatry       Date:  1982-08       Impact factor: 18.112

8.  Uptake inhibition of biogenic amines by newer antidepressant drugs: relevance to the dopamine hypothesis of depression.

Authors:  A Randrup; C Braestrup
Journal:  Psychopharmacology (Berl)       Date:  1977-08-16       Impact factor: 4.530

9.  Clomipramine treatment of obsessive-compulsive disorder. I. A controlled clinical trial.

Authors:  P Thorén; M Asberg; B Cronholm; L Jörnestedt; L Träskman
Journal:  Arch Gen Psychiatry       Date:  1980-11

10.  Obsessive-compulsive disorder. A double-blind trial of clomipramine and clorgyline.

Authors:  T R Insel; D L Murphy; R M Cohen; I Alterman; C Kilts; M Linnoila
Journal:  Arch Gen Psychiatry       Date:  1983-06
View more
  11 in total

Review 1.  Translational approaches to obsessive-compulsive disorder: from animal models to clinical treatment.

Authors:  N A Fineberg; S R Chamberlain; E Hollander; V Boulougouris; T W Robbins
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 2.  Rodent models of obsessive compulsive disorder: Evaluating validity to interpret emerging neurobiology.

Authors:  Isaac Zike; Tim Xu; Natalie Hong; Jeremy Veenstra-VanderWeele
Journal:  Neuroscience       Date:  2016-09-16       Impact factor: 3.590

3.  Catechol-O-Methyltransferase Gene Polymorphisms in Specific Obsessive-Compulsive Disorder Patients' Subgroups.

Authors:  Fernanda Brito Melo-Felippe; Juliana Braga de Salles Andrade; Isabele Gomes Giori; Tamiris Vieira-Fonseca; Leonardo Franklin Fontenelle; Fabiana Barzotti Kohlrausch
Journal:  J Mol Neurosci       Date:  2015-12-19       Impact factor: 3.444

Review 4.  Pharmacological management of treatment-resistant obsessive-compulsive disorder.

Authors:  Anat Abudy; Alzbeta Juven-Wetzler; Joseph Zohar
Journal:  CNS Drugs       Date:  2011-07       Impact factor: 5.749

5.  The role of the striatum in compulsive behavior in intact and orbitofrontal-cortex-lesioned rats: possible involvement of the serotonergic system.

Authors:  Eduardo A Schilman; Oded Klavir; Christine Winter; Reinhard Sohr; Daphna Joel
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

6.  Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele.

Authors:  Richard Delorme; Catalina Betancur; Pauline Chaste; Solen Kernéis; Astrid Stopin; Marie-Christine Mouren; Corinne Collet; Thomas Bourgeron; Marion Leboyer; Jean-Marie Launay
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-03-05       Impact factor: 3.568

7.  Drug treatment of phobias. Efficacy and optimum use.

Authors:  A P Levin; M R Liebowitz
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

Review 8.  Drug treatment of obsessive-compulsive disorder.

Authors:  Michael Kellner
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

Review 9.  Mapping Compulsivity in the DSM-5 Obsessive Compulsive and Related Disorders: Cognitive Domains, Neural Circuitry, and Treatment.

Authors:  Naomi A Fineberg; Annemieke M Apergis-Schoute; Matilde M Vaghi; Paula Banca; Claire M Gillan; Valerie Voon; Samuel R Chamberlain; Eduardo Cinosi; Jemma Reid; Sonia Shahper; Edward T Bullmore; Barbara J Sahakian; Trevor W Robbins
Journal:  Int J Neuropsychopharmacol       Date:  2018-01-01       Impact factor: 5.176

10.  Dopaminergic drug treatment remediates exaggerated cingulate prediction error responses in obsessive-compulsive disorder.

Authors:  Graham K Murray; Franziska Knolle; Karen D Ersche; Kevin J Craig; Sanja Abbott; Shaila S Shabbir; Naomi A Fineberg; John Suckling; Barbara J Sahakian; Edward T Bullmore; Trevor W Robbins
Journal:  Psychopharmacology (Berl)       Date:  2019-06-14       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.